17 years after the vaccine was first approved, hardly any girls are getting vaccinated globally. Poor countries also account for 90% of deaths from cervical cancer. In Japan, they stopped recommending the Jabs back in 2013 because of pressure from vaccine skeptics who had these unfounded safety concerns about the vaccine.
Hints of the long campaign ahead are emerging, but all the operations so far are just drawing the eventual, full-scale battle lines. Cheap vaccinations could save millions of lives lost to cervical cancer; we ask why and where jab rates are falling. And why airlines have more money tied up in Nigeria than in the rest of the world combined.
For full access to print, digital and audio editions of The Economist, try a free 30-day digital subscription by going to www.economist.com/intelligenceoffer